Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Trends Pharmacol Sci. 2013 Nov 26;35(1):10.1016/j.tips.2013.10.008. doi: 10.1016/j.tips.2013.10.008

Strike a Pose: Gαq Complexes at the Membrane

Angeline M Lyon 1, Veronica G Taylor 1, John J G Tesmer 1
PMCID: PMC3880608  NIHMSID: NIHMS535432  PMID: 24287282

Abstract

The heterotrimeric G protein Gαq is a central player in signal transduction, relaying signals from activated G protein-coupled receptors (GPCRs) to effectors and other proteins to elicit changes in intracellular Ca2+, the actin cytoskeleton, and gene transcription. Gαq functions at the surface of the plasma membrane, as do its best characterized targets phospholipase C-β, p63RhoGEF, and GPCR kinase 2 (GRK2). Recent insights into the structure and function of these signaling complexes reveals several recurring themes, including complex multivalent interactions between Gαq, its protein target, and the membrane, that are likely essential for allosteric control and maximum efficiency in signal transduction. Thus, the plasma membrane is not only a source of substrates, but also a key player in the scaffolding of Gαq-dependent signaling pathways.

Keywords: Phospholipase Cβ, p63RhoGEF, ARHGEF25, GRK2, G protein-coupled receptor, heterotrimeric G protein signaling, Gαq, second messengers, phospholipids, membrane, protein structure, crystallography

Signaling by heterotrimeric G protein Gα subunits

The proteins involved in GPCR signaling pathways are essential for vision, blood pressure regulation, cardiac contractility, and numerous other processes 1. Activation of a GPCR by an extracellular signal, such as a photon, hormone, or drug, induces conformational changes that allow the GPCR to function as a guanine nucleotide exchange factor (GEF) for heterotrimeric G protein Gα subunits 2, promoting the binding of GTP by Gα. Once activated, Gα·GTP dissociates from the heterodimeric Gβγ subunits, and both components can bind to and activate downstream effectors at the plasma membrane to elicit changes in the concentration of second messengers such as inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) 3 (Figure 1).

Figure 1. Interplay of Gαq-mediated signaling processes.

Figure 1

GPCR activation catalyzes the binding of GTP to the Gαq subunit, leading to its activation and dissociation from the receptor and the Gβγ heterodimer. Gαq·GTP then interacts with PLCβ or p63RhoGEF, leading to production of the second messengers IP3 and DAG or activation of RhoA, respectively. GRK2 phosphorylation of Gq-coupled receptors initiates homologous desensitization, and GRK2 binding to Gαq·GTP sequesters it from its downstream targets, resulting in phosphorylation-independent desensitization. Meanwhile, RGS proteins catalyze the hydrolysis of GTP on Gαq, leading to its deactivation, and can act on Gαq while it is in complex with p63RhoGEF or GRK2 50, or block its interactions with PLCβ. In addition to a helix-turn-helix motif (orange elbow), Gαq must interact with multiple domains of PLCβ and p63RhoGEF for full functionality. In the case of PLCβ, the N-terminal helix (blue rectangle) and the Ras-like domain of Gαq contact the distal CTD (orange), and the C2 and EF hands domains of the catalytic core, respectively. In the case of p63RhoGEF, the Ras-like domain and C-terminal helix of Gαq bridge the DH and PH domains of p63RhoGEF. Gαq must also simultaneously interact with the membrane via palmitoylation sites at its N-terminus. Disordered regions within the proteins, primarily those bearing the lipid modifications of Gαq, Gβγ, p63RhoGEF, and RhoA to the membrane are shown as black lines. Palmitoyl and geranylgeranyl groups are modeled as orange sticks embedded within the membrane.

The Gα subunit consists of a Ras-like domain with a large α helical domain insertion 3. The guanine nucleotide binding pocket is formed at the interface of the Ras-like and α helical domains, where three “switch” regions (SwI-III) adopt unique conformations dependent on the identity of the bound nucleotide. In the GTP-bound state, the switches help coordinate the catalytic Mg2+ ion, participate in catalysis, and contribute to the effector binding site (Figure 2a, b). In the GDP-bound state, SwII contributes instead to the Gβγ binding site 3. The N-terminus of Gα is lipid-modified (e.g myristoylated and/or palmitoylated) and can form an extended helix that interacts with GPCRs 2, Gβγ subunits 4, 5, and some effectors 6.

Figure 2. Structural and functional features of activated Gαq.

Figure 2

(a) Structure of Gαq in its activated state. Gαq (shown as a gray cartoon with green β strands and red switch regions) is trapped in a GTP hydrolysis transition-like state upon addition of GDP and AlF4, (blue ball and sticks). Mg2+ is shown as a black sphere. The effector binding site is formed in part by the cleft between SwII and the α3 helix. In most structures of activated Gαq, ~30 N-terminal and ~5 C-terminal residues are disordered (not shown). (b) Accessible surface of activated Gαq, in the same orientation as in (a). Residues that primarily contribute to the effector binding site, as defined by the contacts made by the helix-turn-helix motif found in PLCβ and p63RhoGEF, are shown in orange. Note that in each case interactions are also formed with regions of Gαq outside this cleft, which are likely critical for high affinity binding. Residues that primarily contribute to regulator of G protein signaling (RGS) binding, as defined by the structure of the RGS2–Gαq complex 52, are shown in purple. Some residues, particularly in SwII, contribute to both interaction sites. The asterisk demarks the position of a hydrophobic pocket between the SwII and α3 helices that is exploited by the leucine in the ALXXPI motifs of PLCβ and p63RhoGEF. (c, d, e) RGS proteins (green) and effectors (cyan) can often bind their Gα targets (surface representation as in panel b) simultaneously, such that they allosterically regulate the interaction and function of each other. Ternary complexes formed between p63RhoGEF (c) or GRK2 (d) with the RGS2–Gαq complex have been confirmed biochemically 64. The RGS9–Gαi/t–PDEγ complex (e) is the only ternary complex that has been structurally characterized 65. To create the models shown in panels c and d, the RGS2–Gαq complex 67 was superimposed on the p63RhoGEF 11 and GRK2 14 complexes, respectively, using the Gα subunit for alignment. Only the helical bundle subdomain of the GRK2 RH domain is shown for clarity. Yellow regions correspond to helical elements that engage the effector binding site as defined in panel b.

The focus of this review is on the interactions formed by activated Gαq, which represents one of the four canonical subfamilies of Gα subunits (Gαs, Gαi/o, Gαq/11 and Gα12/13). The other members of this subfamily include Gα11, Gα14, and Gα15/16. Gαq subfamily members are activated by GPCRs that respond to hormones and neurotransmitters such as norepinephrine, endothelin, and glutamate 7, and play important roles throughout the cardiovascular and nervous systems. Classically, Gαq activates phospholipase C-β (PLCβ), which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) to generate the second messengers inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), leading to increases in intracellular Ca2+ and activation of protein kinase C 8, 9. More recently, it was discovered that Gαq also activates the guanine nucleotide exchange factor p63RhoGEF (ARHGEF25) and its homologs Trio and Duet 1013, thereby linking GPCRs to the activation of RhoA and control of the actin cytoskeleton. In addition, Gαq binds to GPCR kinase 2 (GRK2) 14, an enzyme that initiates homologous desensitization by phosphorylating activated GPCRs 15. However, GRK2 is not activated via binding Gαq. Instead, it seems to sequester Gαq from its other targets in a form of phosphorylation-independent desensitization 1619 (Figure 1). Not all members of the Gαq subfamily interact with these targets in the same manner. Gα16 does not bind appreciably to GRK2 20, and binds to but does not activate p63RhoGEF 21

Structural and functional studies of activated Gαq in complex with PLCβ3 6, 22, p63RhoGEF 11, and GRK2 14 reveal some general themes. PLCβ, p63RhoGEF, and GRK2 all must interact with the membrane and, in some cases, with other peripheral membrane proteins for optimal catalytic efficiency. A specific orientation of these enzymes with respect to the membrane plane is essential for their function. All three enzymes engage the effector binding site of Gαq using exposed hydrophobic residues on helical elements. Unexpectedly, comparison of the likely membrane-bound orientation of Gαq in complex with PLCβ, p63RhoGEF, and GRK2 reveals that Gαq adopts a similar orientation with respect to the membrane plane in each assembly (Figure 3). It is also clear that the membrane itself plays one or more active roles in the function of these complexes: it can enhance the affinity of signaling components by co-localization, serve as a scaffold for the assembly of high order assemblies, and/or optimize the orientation of these proteins for maximum signaling efficiency.

Figure 3. Gαq complexes modeled at the cell membrane.

Figure 3

(a) The Gαq–PLCβ3 complex. PLCβ3 (cyan) is oriented such that its active site is in close proximity to the lipid bilayer. The catalytic Ca2+ (black sphere) defines the location of the active site. Residues that constitute the hydrophobic ridge, which may anchor the active site in the membrane, are shown in green spheres, and the conserved basic region of the distal CTD, thought to form the primary membrane binding site, is shown in blue spheres. The helix-turn-helix (Hα1/Hα2) in the proximal CTD of PLCβ (yellow) docks to the effector binding site of Gαq (shown as in Figure 2b). The end of the proximal CTD and start of the distal CTD are denoted by blue asterisks. The palmitoyl groups at the N-terminus of Gαq are shown as red sticks inserted within the membrane (grey rectangle). All disordered regions, including the X–Y linker (black) proposed to be displaced upon interaction with the membrane, are shown as dashed lines. To generate this model, the distal CTD in complex with the Gαq N-terminal helix and the Gαq–catalytic core complex from PDB entry 4GNK were each independently docked at a shared surface. The Gαq N-terminus-distal CTD complex was then rotated in the plane of this surface to allow the N-terminal helix to join the Ras-like domain of Gαq. (b) The Gαq–PLCβ3 complex as viewed from the perspective of the putative membrane surface. (c) The Gαq–p63RhoGEF RhoA–complex. The DH (light green) and PH (cyan) domains form the primary binding sites for RhoA (yellow accessible surface with pink switch regions) and activated Gαq (shown as in Figure 2b). As in PLCβ, the p63RhoGEF catalytic core has an extension that forms a helix-turn-helix (yellow) which docks in the Gαq effector binding site. The orientation of Gαq–p63RhoGEF–RhoA complex at the membrane is less well determined, as the membrane binding determinants are all found in disordered elements: the C-terminus of RhoA (13 disordered residues containing a polybasic region ending in a geranylgeranyl group), the N-terminus of p63RhoGEF (three palmitoylation sites positioned ~125 residues N-terminal to the DH domain), and the N-terminus of Gαq (two palmitoylation sites ~25 residues N-terminal to the beginning of the Ras-like domain). (d) The Gαq–p63RhoGEF–RhoA complex viewed from the perspective of the membrane. Red asterisks mark the last ordered residues at the C-terminus of RhoA and N-terminus of Gαq, which are attached to flexible sequences that are lipid modified. (e) The Gαq–GRK2–Gβγ complex. The RH domain of GRK2 (cyan) binds to the effector binding site of Gαq using a helix (yellow) analogous to the first helix of helix-turn-helix motif found in PLCβ and p63RhoGEF. GRK2 binds to the membrane primarily via its PH domain, which binds to both PIP2 and heterotrimeric Gβγ subunits (blue and green), which are prenylated. GRK2 is modeled in an active configuration with an ordered N- terminal helix (demarked by “N”) based on a recent structure of GRK6 46. This helix has amphipathic character and is believed to interact with either activated GPCRs in the membrane or with the phospholipid bilayer itself 45. (f) The Gαq–GRK2–Gβγ complex viewed from the perspective of the membrane surface.

Scaffolding interactions in the activation of PLCβ by Gαq

PLCβ enzymes comprise two major regions: a catalytic core responsible for PIP2 hydrolysis and a ~400 residue C-terminal extension required for Gαq regulation and membrane association (Figure 3a, b). The catalytic core is conserved across all PLC isozymes 23 and contains an autoinhibitory element called the X–Y linker 24, which is immediately adjacent to the active site. This linker is poorly conserved but contains highly acidic stretches of amino acids in human PLCβ isoforms. In all PLCβ crystal structures reported to date, the C-terminal residues of the linker are ordered and occlude the active site 9. It has been proposed this linker is dislodged by electrostatic repulsion when the PLCβ catalytic core is brought in close proximity to the negatively charged inner leaflet of the plasma membrane 24. Also adjacent to the active site is the so-called hydrophobic ridge, a series of loops with exposed hydrophobic residues believed to insert into the membrane during catalysis 25 (Figure 3a, b).

The C-terminal extension can be subdivided into two domains. The first 45 amino acids form the proximal C-terminal domain (CTD), comprising the primary Gαq binding site and an autoinhibitory helix (Hα2′). In the absence of Gαq, the first 25 amino acids of the proximal CTD are disordered 26. Upon Gαq binding, these residues form a helix-turn-helix (Hα1/Hα2) that docks into the effector binding site of Gαq via a conserved motif, ALXXPI (where X represents any amino acid) 6, 22. An additional contact between Gαq and PLCβ is made by an asparagine residue within the catalytic core that interacts with the active site of Gαq to increase the rate of GTP hydrolysis. Thus, PLCβ functions as its own GTPase activating protein (GAP), regulating the duration of its own signal 22. Under basal conditions, the Hα2′ helix of the proximal CTD interacts with a conserved cleft within the PLCβ catalytic core. Disruption of the Hα2′-core interaction in human PLCβ3 increases basal activity up to ~50–fold over wild-type and decreases the efficacy of Gαq activation, suggesting that Gαq activation of PLCβ includes an allosteric component 26.

The last ~300 residues of the C-terminal extension form the distal CTD, a long coiled-coil domain 6, 27 required for maximum basal and Gαq-stimulated activity and for membrane association 22, 26, 2831 (Figure 3a, b). The distal CTD features two conserved surfaces. The first is an extended positively charged region formed by clusters of basic residues along one face of the domain. Mutation of these residues decreases Gαq-stimulated activity and particulate association, suggesting they represent the primary membrane binding surface 28, 31, 32. The second surface contains a cluster of conserved hydrophobic residues that binds the N-terminal helix of Gαq in the crystal structure of the Gαq–PLCβ3 complex 6. Abrogation of this interaction diminished maximal Gαq-stimulated activity, as did loss of Gαq palmitoylation.

Direct interactions between PLCβ and Gαq increases the rate of PIP2 hydrolysis by up to ~80–fold over basal. However, although Gαq is palmitoylated at its N-terminus and localized at the membrane 33, there are no quantitative studies demonstrating that interactions with Gαq increase PLCβ membrane association 34, 35, and thus membrane recruitment on its own does not provide a holistic model for activation. Instead, it has been proposed that in the absence of Gαq, PLCβ enzymes are in equilibrium between cytosolic and membrane-associated populations 6, 35, which may be regulated in part through direct interactions between the distal CTD and the catalytic core, as observed in crystals and in solution by cryo-electron microscopy 6. Gαq binds to the Hα1/Hα2 helix-turn-helix and displaces the auto-inhibitory Hα2′ helix from the catalytic core, allosterically activating PLCβ. Meanwhile, the distal CTD simultaneously interacts with the membrane and with the N-terminal helix of Gαq in a manner that helps the Gαq–catalytic core complex adopt a specific orientation with respect to the membrane surface 6. The resulting electrostatic repulsion between the membrane and acidic regions in the X–Y linker helps to open the active site, allowing insertion of the hydrophobic ridge into the membrane and binding of the substrate PIP2 (Figure 3a). Thus, the distal CTD and the membrane can be thought of as scaffolds that not only help optimize the orientation of the Gαq–catalytic core complex, but also allosterically activate it. Higher order scaffolding interactions are known to occur. Complexes that include GPCRs can be mediated by proteins such as WD40 repeat protein 36 (WDR36), which has been reported to interact with Gαq, PLCβ and the thromboxane A2 receptor 36, and well-characterized scaffolding proteins such as InaD and Na+-H+ exchange regulatory factor (NHERF) 37.

Despite recent progress in understanding the molecular mechanisms of Gαq-dependent activation, many questions remain. It is unclear whether membrane binding induces conformational changes within the catalytic core of PLCβ and whether displacement of the segment of the X–Y linker that occludes the active site also contributes to structural rearrangements. The mechanism by which Hα2′ mediates autoinhibition is currently unknown. Finally, given its similarity to Bin–Amphiphysin–Rvs domains, the distal CTD may play other roles in regulating Gαq-stimulated activity, such as by altering the local structure of the membrane itself 6.

Membrane scaffolding of the Gαq–p63RhoGEF–RhoA signaling complex

Although Gαq has been reported to interact with other RhoGEFs 3840, p63RhoGEF is the best characterized direct link between Gq-coupled receptors and RhoA 10. p63RhoGEF plays a role in neurite outgrowth 41, 42, and in smooth muscle cells it contributes to muscle contraction by promoting GTP binding by RhoA in response to activation of angiotensin II, endothelin-1 and phenylephrine-responsive GPCRs 4345. Recent studies also suggest that p63RhoGEF plays an important role in breast carcinoma cell chemotaxis 46, 47 and osteoblast diffentiation 48. Two related RhoGEFs, Trio and Duet, have also been found to activate RhoA in response to binding Gαq 11, 13. In C. elegans, the Trio homolog is required for proper acetylcholine-stimulated locomotion and egg-laying 12. Interestingly, Gα16 binds to, but does not activate p63RhoGEF, which can lead to inhibition of Gα16-mediated activation of PLCβ 21. Conversely, Gα16 could also inhibit the activation of p63RhoGEF mediated by other Gαq subfamily members, although this remains to be demonstrated experimentally.

As a member of the Dbl family of RhoGEFs, the catalytic core of p63RhoGEF contains the characteristic Dbl homology (DH) domain, which harbors the principal binding site for RhoA, immediately followed by a pleckstrin homology (PH) domain that often plays a regulatory role in these enzymes. In the case of p63RhoGEF, the PH domain inhibits the catalytic activity of the DH domain, but the molecular mechanism for this is not fully understood. Binding of activated Gαq leads to allosteric activation of p63RhoGEF, the most obvious manifestation of which is an increase in the affinity of p63RhoGEF for apo-RhoA 49.

The crystal structure of the Gαq–p63RhoGEF–RhoA complex reveals that Gαq binds in a manner that bridges the DH and PH domains of p63RhoGEF 11 (Figure 3c, d). Like PLCβ, the DH/PH catalytic core of p63RhoGEF features a C-terminal extension, also conserved in Trio and Duet 13, which forms a helix-turn-helix element that docks into the effector-binding site of Gαq. Strikingly, this extension contains the same ALXXPI motif used in PLCβ isozymes to bind the effector binding site on Gαq. Mutation of the conserved leucine in this motif (L859 in human PLCβ3, L475 in human p63RhoGEF) is sufficient to eliminate Gαq binding 11, 13, 22, 31. Consequently, PLCβ and p63RhoGEF cannot simultaneously interact with a single Gαq molecule 10, and would therefore appear to represent competitive pathways in cells where both enzymes are expressed. However, in C. elegans, the activity of both enzymes is required for proper function of the neuromuscular junction, suggesting there may be distinct pools of Gαq scaffolded in close proximity to each effector enzyme at the cell membrane 12.

The interactions between the C-terminal extension of p63RhoGEF and Gαq are further stabilized by bridging interactions of the DH domain with the Ras-like domain of Gαq. Mutation of residues involved in this latter interface decreases Gαq-mediated activation but had little affect on affinity 11, including those converting positions at the C-terminus of Gαq to their equivalents in Gα16 49. These results suggest that the bridging interaction of Gαq serves to constrain the relative orientation of the DH and PH domains 49. Indeed, comparison with structures of closely related DH/PH domains indicates that the relative orientation of the DH and PH domains in the Gαq–p63RhoGEF complex is atypical. Thus, in the basal state, either the p63RhoGEF PH domain occludes the RhoA binding site, or the linker helix connecting the DH and PH domains, which forms an important portion of the interface with apo-RhoA (Figure 3d), is not in an optimal configuration. When the Gαq–p63RhoGEF–RhoA complex is positioned such that all the lipid modifications (geranylgeranyl in RhoA, and palmitoyl in Gαq and p63RhoGEF) are positioned to engage the membrane (Figure 3c), the orientation of Gαq is similar to that observed in the Gαq–PLCβ complex 6, 22. However, unlike PLCβ, the entire complex is likely offset from the membrane due to the length of disordered elements bearing the lipid modifications (Figure 3c, d). Such an offset is consistent with the lack of an obvious basic electrostatic surface on the Gαq–p63RhoGEF–RhoA complex that would interact with the negatively charged inner leaflet of the membrane.

In cells, p63RhoGEF is constitutively localized to the cell membrane by virtue of three palmitoylated cysteines at its N-terminus. Mutation or deletion of these cysteines abrogates membrane association and activity of p63RhoGEF in cells, but not in vitro 50. This result indicates the interaction between p63RhoGEF and RhoA is not of sufficient affinity in vivo to drive activation in the absence of co-localization mediated by the membrane. A recent study showed that GEFT, a splice variant of p63RhoGEF that lacks N-terminal palmitoylation sites, is not membrane associated and does not efficiently couple to Gαq in cells unless it is artificially targeted to the plasma membrane. This study further concluded that the membrane plays an important role in increasing local concentration, but not encounter times 51. Lipid modifications in the p63RhoGEF complex might also drive these proteins into raft-like domains, where their effective affinity would be even higher and result in highly localized signal amplification 52.

GRK2: a non-canonical Gαq interaction partner and G protein scaffold

The catalytic core of GRK2 consists of an N-terminal RGS homology (RH) domain and a kinase domain 53. The GRK2 RH domain binds activated Gαq with high affinity 14, 20, 54, 55, but this ability seems unique to the GRK2 subfamily of GRKs. GRK2 also has a C-terminal PH domain that binds to Gβγ subunits and PIP2 (Figure 3e, f), which are essential for GRK2 membrane recruitment 56 and activity in vivo 57, but not in vitro 58, echoing the role of N-terminal palmitoylation in p63RhoGEF. Crystal structures of GRK2 alone and in complex with Gβγ, sequence conservation, and biochemical studies identified an extended basic surface along one face of GRK2 that likely interacts with the membrane 53, 57, 59, which includes the prenyl modification of Gβγ, the lipid binding surface of the GRK2 PH domain, and the N-terminal helix of GRK2, which has been proposed to either interact directly with activated GPCRs 60 or phospholipid bilayers 61 (Figure 3e, f). Recently, sum frequency generation (SFG) spectroscopy has provided experimental support for the proposed orientation of the GRK2–Gβγ complex on model phospholipid bilayers 62.

The Gαq interaction with GRK2 shares several structural similarities with those formed with PLCβ and p63RhoGEF. The RH domain of GRK2 binds the effector binding site of Gαq using a helix analogous to the Hα1 helix of PLCβ3 and the first helix of the p63RhoGEF C-terminal extension 14. Although it lacks an ALXXPI motif, a conserved leucine (human GRK2 L118) plays a structurally equivalent role to the leucine found in this motif and is likewise essential for Gαq binding 54. There are significant differences in the GRK2 RH domain interface that confer its specificity among Gαq subfamily members20. Gαq-Tyr261 forms multiple hydrogen bonds with GRK2 that cannot be formed by the leucine at this position in Gα16, and mutation of Gαq-Tyr261 to leucine abrogates activation-dependent binding to GRK2 14. Thus, the GRK2 RH domain can be thought of as a scaffolding domain that presents the associated protein kinase and PH domains to the membrane in a manner that allows simultaneous binding of activated receptors, Gβγ subunits, and Gαq (Figure 3e, f). For its part, the membrane co-localizes these proteins, thereby enhancing their effective affinity, and allosterically activates GRK2 via the binding of PIP2 to the PH domain. When the Gαq–GRK2 complex is positioned in its expected membrane binding orientation, Gαq once again adopts a similar orientation to that observed in the PLCβ and p63RhoGEF complexes.

A conserved pose in Gαq signaling

In all published structures of its protein complexes, the predicted orientation of activated Gαq at the membrane is similar (Figure 3). Its position in the p63RhoGEF complex is the most distinct, but in this case there is a greater degree of uncertainty about the membrane orientation of the complex. Is this common pose a coincidence, or is there a functional basis? All the substrates of known Gαq targets are integral membrane components (e.g. PIP2, RhoA, or GPCRs). The N-terminus of Gαq is disordered in the absence of a protein interaction partner and palmitoylated, which allows the Ras-like domain of the Gαq core to remain tethered to the membrane following activation and provides flexibility for Gα to engage its targets in a manner that does not interfere with their ability to interact with the membrane, their substrates, or other peripheral or integral membrane protein partners. Indeed, PLCβ, p63RhoGEF, GRK2 and their complexes must all engage the membrane via multiple sites for efficient signal transduction, and having Gαq offset from the membrane and on the periphery of the complex likely facilitates these interactions. It is also possible that the pose of Gαq also serves to accommodate higher order scaffolding interactions.

PLCβ is unique among the Gαq binding partners in that it has significant intrinsic GAP activity towards Gαq. However, the interactions of p63RhoGEF and GRK2 with Gαq do not preclude the binding of RGS proteins like RGS2, which are also membrane localized 63 and can readily fit in the space between the membrane surface and these complexes when docked on Gαq 64 (Figure 2c, d). Thus, the orientation of Gαq in these latter complexes may also permit the cell to regulate the duration of these interactions, analogous to how RGS9 modulates the duration of the Gαt–phosphodiesterase γ (PDEγ) complex during phototransduction 65 (Figure 2e). In the case of the Gαq–GRK2 complex, the binding of RGS proteins could also contribute to phosphorylation-independent inhibition of Gαq signaling, wherein GRK2 not only sequesters activated Gαq, but also presents it to RGS proteins for rapid deactivation. In the case of PLCβ, RGS proteins such as RGS2 likely regulate signaling by serving as an effector antagonist 66 because the PLCβ and RGS2 binding sites on Gαq extensively overlap 67.

Concluding remarks

As the Gαq complexes described above reveal, the interactions between G protein, effector, and membrane can be quite complex, as befitting pathways of central importance to cell physiology. The importance of the membrane in these interactions is evident, whether it simply supplies the enzyme substrate or regulatory lipids for the target enzyme, enhances the local concentration of the interacting groups, or helps to orchestrate an allosteric change in the Gαq target. Yet the membrane is clearly not the only player. In the future it will be important to describe the molecular basis for how scaffolding proteins such as WDR36 organize the Gαq signaling pathway in a manner that also promotes efficient interactions with GPCRs and/or downstream second messenger targets such as protein kinase C 36, 37. It is possible that such higher order scaffolding complexes also help to segregate the activation of distinct pools of Gαq effectors, as suggested by the requirement for both p63RhoGEF and PLCβin proper locomotion and egg laying in C. elegans 12 (Figure 1). The complexity of these interactions, however, allows for many layers of regulation and many opportunities for selective therapeutic intervention. For example, the binding site for the Hα2′ helix on the PLC catalytic core may represent a allosteric regulatory pocket unique to the PLCβ isoforms 9, and compounds that inhibit the palmitoylation of p63RhoGEF will likey inhibit chemotaxis in cancer cells 51.

The membrane orientation of other Gα subfamily complexes, and consequently the role of the membrane in regulating their activity, remains poorly understood. This gap in our knowledge occurs because the membrane binding determinants in crystal structures of their complexes are typically either truncated and/or not resolved. For example, the role of the transmembrane domains of mammalian adenylyl cyclase (AC) remains controversial 68 despite examples of accessory domains in ACs playing a critical role in dictating the conformation of its catalytic core 69. The orientation of the Gαs–adenylyl cyclase catalytic core structure 70 relative to its integral membrane domains and the functional consequence of this orientation is not known. Such knowledge will be essential for a comprehensive understanding of how scaffolding interactions, mediated by the membrane and/or other proteins, help dictate the strength, duration, and fidelity of GPCR signaling.

  • q and its target proteins signal in a highly membrane-dependent manner

  • The membrane plays a key role in organizing and regulating high order Gαq assemblies

  • q adopts a similar pose with respect to the membrane when bound to structurally diverse proteins

  • The orientation of Gαq is enforced by multivalent interactions with its targets

Acknowledgments

This work was supported by US National Institutes of Health (NIH) grants HL086865, and HL071818 (J.J.G.T.) and an American Heart Association Post-Doctoral Fellowship 13POST1637009 (A.M.L.).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Neves SR, et al. G protein pathways. Science. 2002;296:1636–1639. doi: 10.1126/science.1071550. [DOI] [PubMed] [Google Scholar]
  • 2.Rasmussen SG, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549–555. doi: 10.1038/nature10361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sprang SR, et al. Structural basis of effector regulation and signal termination in heterotrimeric Gα proteins. Adv Protein Chem. 2007;74:1–65. doi: 10.1016/S0065-3233(07)74001-9. [DOI] [PubMed] [Google Scholar]
  • 4.Lambright DG, et al. The 2.0 Å crystal structure of a heterotrimeric G protein. Nature. 1996;379:311–319. doi: 10.1038/379311a0. [DOI] [PubMed] [Google Scholar]
  • 5.Wall MA, et al. The structure of the G protein heterotrimer Giα1β1γ2. Cell. 1995;83:1047–1058. doi: 10.1016/0092-8674(95)90220-1. [DOI] [PubMed] [Google Scholar]
  • 6.Lyon AM, et al. Full-length Galpha(q)-phospholipase C-beta3 structure reveals interfaces of the C-terminal coiled-coil domain. Nat Struct Mol Biol. 2013;20:355–362. doi: 10.1038/nsmb.2497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hubbard KB, Hepler JR. Cell signalling diversity of the Gqα family of heterotrimeric G proteins. Cell Signal. 2006;18:135–150. doi: 10.1016/j.cellsig.2005.08.004. [DOI] [PubMed] [Google Scholar]
  • 8.Gresset A, et al. The phospholipase C isozymes and their regulation. Subcell Biochem. 2012;58:61–94. doi: 10.1007/978-94-007-3012-0_3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lyon AM, Tesmer JJ. Structural Insights into Phospholipase C-beta Function. Mol Pharmacol. 2013;84:488–500. doi: 10.1124/mol.113.087403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lutz S, et al. The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. J Biol Chem. 2005;280:11134–11139. doi: 10.1074/jbc.M411322200. [DOI] [PubMed] [Google Scholar]
  • 11.Lutz S, et al. Structure of Gαq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science. 2007;318:1923–1927. doi: 10.1126/science.1147554. [DOI] [PubMed] [Google Scholar]
  • 12.Williams SL, et al. Trio’s Rho-specific GEF domain is the missing Gαq effector in C. elegans. Genes Dev. 2007;21:2731–2746. doi: 10.1101/gad.1592007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rojas RJ, et al. Gαq directly activates p63RhoGEF and Trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain. J Biol Chem. 2007;282:29201–29210. doi: 10.1074/jbc.M703458200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tesmer VM, et al. Snapshot of activated G proteins at the membrane: the Gαq-GRK2-Gβγ complex. Science. 2005;310:1686–1690. doi: 10.1126/science.1118890. [DOI] [PubMed] [Google Scholar]
  • 15.Gurevich EV, et al. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacology & therapeutics. 2012;133:40–69. doi: 10.1016/j.pharmthera.2011.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Iwata K, et al. Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. J Biol Chem. 2005;280:2197–2204. doi: 10.1074/jbc.M408834200. [DOI] [PubMed] [Google Scholar]
  • 17.Luo J, et al. M3 muscarinic acetylcholine receptor-mediated signaling is regulated by distinct mechanisms. Mol Pharmacol. 2008;74:338–347. doi: 10.1124/mol.107.044750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ribeiro FM, et al. Phosphorylation-independent regulation of metabotropic glutamate receptor 5 desensitization and internalization by G protein-coupled receptor kinase 2 in neurons. J Biol Chem. 2009;284:23444–23453. doi: 10.1074/jbc.M109.000778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lee IH, et al. Regulation of the epithelial Na+ channel by the RH domain of G protein-coupled receptor kinase, GRK2, and Galphaq/11. J Biol Chem. 2011;286:19259–19269. doi: 10.1074/jbc.M111.239772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Day PW, et al. Differential interaction of GRK2 with members of the Gαq family. Biochemistry. 2003;42:9176–9184. doi: 10.1021/bi034442+. [DOI] [PubMed] [Google Scholar]
  • 21.Yeung WW, Wong YH. The RhoA-specific guanine nucleotide exchange factor p63RhoGEF binds to activated Gα16 and inhibits the canonical phospholipase Cβ pathway. Cell Signal. 2009;21:1317–1325. doi: 10.1016/j.cellsig.2009.03.017. [DOI] [PubMed] [Google Scholar]
  • 22.Waldo GL, et al. Kinetic scaffolding mediated by a phospholipase C-β and Gq signaling complex. Science. 2010;330:974–980. doi: 10.1126/science.1193438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kadamur G, Ross EM. Mammalian phospholipase C. Annu Rev Physiol. 2013;75:127–154. doi: 10.1146/annurev-physiol-030212-183750. [DOI] [PubMed] [Google Scholar]
  • 24.Hicks SN, et al. General and versatile autoinhibition of PLC isozymes. Mol Cell. 2008;31:383–394. doi: 10.1016/j.molcel.2008.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Essen LO, et al. Structural mapping of the catalytic mechanism for a mammalian phosphoinositide-specific phospholipase C. Biochemistry. 1997;36:1704–1718. doi: 10.1021/bi962512p. [DOI] [PubMed] [Google Scholar]
  • 26.Lyon AM, et al. An autoinhibitory helix in the C-terminal region of phospholipase C-β mediates Gαq activation. Nat Struct Mol Biol. 2011;18:999–1005. doi: 10.1038/nsmb.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Singer AU, et al. A unique fold of phospholipase C-β mediates dimerization and interaction with Gαq. Nat Struct Biol. 2002;9:32–36. doi: 10.1038/nsb731. [DOI] [PubMed] [Google Scholar]
  • 28.Kim CG, et al. The role of carboxyl-terminal basic amino acids in Gqα-dependent activation, particulate association, and nuclear localization of phospholipase C-β1. J Biol Chem. 1996;271:21187–21192. doi: 10.1074/jbc.271.35.21187. [DOI] [PubMed] [Google Scholar]
  • 29.Lee S, et al. Activation of phospholipase C-β2 mutants by G protein αq and βγ subunits. J Biol Chem. 1993;268:25952–25957. [PubMed] [Google Scholar]
  • 30.Ilkaeva O, et al. Mutations in the carboxyl-terminal domain of phospholipase Cβ 1 delineate the dimer interface and a potential Gαq interaction site. J Biol Chem. 2002;277:4294–4300. doi: 10.1074/jbc.M109612200. [DOI] [PubMed] [Google Scholar]
  • 31.Adjobo-Hermans MJ, et al. PLCβ isoforms differ in their subcellular location and their CT-domain dependent interaction with Gαq. Cell Signal. 2013;25:255–263. doi: 10.1016/j.cellsig.2012.09.022. [DOI] [PubMed] [Google Scholar]
  • 32.Wu D, et al. Identification of critical regions on phospholipase C-β 1 required for activation by G-proteins. J Biol Chem. 1993;268:3704–3709. [PubMed] [Google Scholar]
  • 33.Hepler JR, et al. Functional importance of the amino terminus of Gqα. J Biol Chem. 1996;271:496–504. doi: 10.1074/jbc.271.1.496. [DOI] [PubMed] [Google Scholar]
  • 34.Gutman O, et al. Differential regulation of phospholipase C-β2 activity and membrane interaction by Gαq, Gβ1γ2, and Rac2. J Biol Chem. 2010;285:3905–3915. doi: 10.1074/jbc.M109.085100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Illenberger D, et al. Rac2 regulation of phospholipase C-β 2 activity and mode of membrane interactions in intact cells. J Biol Chem. 2003;278:8645–8652. doi: 10.1074/jbc.M211971200. [DOI] [PubMed] [Google Scholar]
  • 36.Cartier A, et al. WDR36 acts as a scaffold protein tethering a G-protein-coupled receptor, Gαq and phospholipase Cβ in a signalling complex. J Cell Sci. 2011;124:3292–3304. doi: 10.1242/jcs.085795. [DOI] [PubMed] [Google Scholar]
  • 37.Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol. 2009;10:819–830. doi: 10.1038/nrm2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sagi SA, et al. Physical and functional interactions of Gαq with Rho and its exchange factors. J Biol Chem. 2001;276:15445–15452. doi: 10.1074/jbc.M008961200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Booden MA, et al. Leukemia-associated Rho guanine nucleotide exchange factor promotes Gαq-coupled activation of RhoA. Mol Cell Biol. 2002;22:4053–4061. doi: 10.1128/MCB.22.12.4053-4061.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Pfreimer M, et al. LARG links histamine-H1-receptor-activated Gq to Rho-GTPase-dependent signaling pathways. Cell Signal. 2012;24:652–663. doi: 10.1016/j.cellsig.2011.10.014. [DOI] [PubMed] [Google Scholar]
  • 41.Bryan B, et al. GEFT, a Rho family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation. J Biol Chem. 2004;279:45824–45832. doi: 10.1074/jbc.M406216200. [DOI] [PubMed] [Google Scholar]
  • 42.Bryan BA, et al. The Rho-family guanine nucleotide exchange factor GEFT enhances retinoic acid- and cAMP-induced neurite outgrowth. Journal of neuroscience research. 2006;83:1151–1159. doi: 10.1002/jnr.20814. [DOI] [PubMed] [Google Scholar]
  • 43.Wuertz CM, et al. p63RhoGEF--a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells. FASEB J. 2010;24:4865–4876. doi: 10.1096/fj.10-155499. [DOI] [PubMed] [Google Scholar]
  • 44.Momotani K, et al. p63RhoGEF couples Galpha(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. Circ Res. 2011;109:993–1002. doi: 10.1161/CIRCRESAHA.111.248898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Momotani K, Somlyo AV. p63RhoGEF: a new switch for G(q)-mediated activation of smooth muscle. Trends in cardiovascular medicine. 2012;22:122–127. doi: 10.1016/j.tcm.2012.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hayashi A, et al. p63RhoGEF-mediated formation of a single polarized lamellipodium is required for chemotactic migration in breast carcinoma cells. Febs Lett. 2013;587:698–705. doi: 10.1016/j.febslet.2013.01.043. [DOI] [PubMed] [Google Scholar]
  • 47.Tang X, et al. GPR116, an Adhesion G-Protein-Coupled Receptor, Promotes Breast Cancer Metastasis via the Galphaq-p63RhoGEF-Rho GTPase Pathway. Cancer Res. 2013 doi: 10.1158/0008-5472.CAN-13-1049. [DOI] [PubMed] [Google Scholar]
  • 48.Siegert P, et al. Pasteurella multocida toxin prevents osteoblast differentiation by transactivation of the MAP-kinase cascade via the Galpha(q/11)--p63RhoGEF--RhoA axis. PLoS Pathog. 2013;9:e1003385. doi: 10.1371/journal.ppat.1003385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Shankaranarayanan A, et al. Gαq allosterically activates and relieves autoinhibition of p63RhoGEF. Cell Signal. 2010;22:1114–1123. doi: 10.1016/j.cellsig.2010.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Aittaleb M, et al. Plasma membrane association of p63 Rho guanine nucleotide exchange factor (p63RhoGEF) is mediated by palmitoylation and is required for basal activity in cells. J Biol Chem. 2011;286:34448–34456. doi: 10.1074/jbc.M111.273342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Goedhart J, et al. Signaling efficiency of Galphaq through its effectors p63RhoGEF and GEFT depends on their subcellular location. Scientific reports. 2013;3:2284. doi: 10.1038/srep02284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. doi: 10.1038/35036052. [DOI] [PubMed] [Google Scholar]
  • 53.Lodowski DT, et al. Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gβγ. Science. 2003;300:1256–1262. doi: 10.1126/science.1082348. [DOI] [PubMed] [Google Scholar]
  • 54.Day PW, et al. Characterization of the GRK2 binding site of Gαq. J Biol Chem. 2004;279:53643–53652. doi: 10.1074/jbc.M401438200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Carman CV, et al. Selective regulation of Gαq/11 by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem. 1999;274:34483–34492. doi: 10.1074/jbc.274.48.34483. [DOI] [PubMed] [Google Scholar]
  • 56.Touhara K, et al. Binding of G protein βγ-subunits to pleckstrin homology domains. J Biol Chem. 1994;269:10217–10220. [PubMed] [Google Scholar]
  • 57.Carman CV, et al. Mutational analysis of Gbetagamma and phospholipid interaction with G protein-coupled receptor kinase 2. J Biol Chem. 2000;275:10443–10452. doi: 10.1074/jbc.275.14.10443. [DOI] [PubMed] [Google Scholar]
  • 58.Pitcher JA, et al. Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science. 1992;257:1264–1267. doi: 10.1126/science.1325672. [DOI] [PubMed] [Google Scholar]
  • 59.Lodowski DT, et al. The role of Gβγ and domain interfaces in the activation of G protein-coupled receptor kinase 2. Biochemistry. 2005;44:6958–6970. doi: 10.1021/bi050119q. [DOI] [PubMed] [Google Scholar]
  • 60.Boguth CA, et al. Molecular basis for activation of G protein-coupled receptor kinases. EMBO J. 2010;29:3249–3259. doi: 10.1038/emboj.2010.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Noble B, et al. Development of a yeast bioassay to characterize G protein-coupled receptor kinases. Identification of an NH2-terminal region essential for receptor phosphorylation. J Biol Chem. 2003;278:47466–47476. doi: 10.1074/jbc.M308257200. [DOI] [PubMed] [Google Scholar]
  • 62.Boughton AP, et al. Heterotrimeric G protein beta1gamma2 subunits change orientation upon complex formation with G protein-coupled receptor kinase 2 (GRK2) on a model membrane. Proc Natl Acad Sci U S A. 2011;108:E667–673. doi: 10.1073/pnas.1108236108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Gu S, et al. Unique hydrophobic extension of the RGS2 amphipathic helix domain imparts increased plasma membrane binding and function relative to other RGS R4/B subfamily members. J Biol Chem. 2007;282:33064–33075. doi: 10.1074/jbc.M702685200. [DOI] [PubMed] [Google Scholar]
  • 64.Shankaranarayanan A, et al. Assembly of high order Gαq-effector complexes with RGS proteins. J Biol Chem. 2008;283:34923–34934. doi: 10.1074/jbc.M805860200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Slep KC, et al. Structural determinants for regulation of phosphodiesterase by a G protein at 2.0 Å. Nature. 2001;409:1071–1077. doi: 10.1038/35059138. [DOI] [PubMed] [Google Scholar]
  • 66.Heximer SP, et al. RGS2/G0S8 is a selective inhibitor of Gqα function. Proc Natl Acad Sci U S A. 1997;94:14389–14393. doi: 10.1073/pnas.94.26.14389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Nance MR, et al. Structural and functional analysis of the regulator of G protein signaling 2-Galphaq complex. Structure. 2013;21:438–448. doi: 10.1016/j.str.2012.12.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sunahara RK, Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv. 2002;2:168–184. doi: 10.1124/mi.2.3.168. [DOI] [PubMed] [Google Scholar]
  • 69.Tews I, et al. The structure of a pH-sensing mycobacterial adenylyl cyclase holoenzyme. Science. 2005;308:1020–1023. doi: 10.1126/science.1107642. [DOI] [PubMed] [Google Scholar]
  • 70.Tesmer JJ, et al. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsα·GTPγS. Science. 1997;278:1907–1916. doi: 10.1126/science.278.5345.1907. [DOI] [PubMed] [Google Scholar]

RESOURCES